Appendix H: Appraisal checklists, evidence tables, GRADE and economic profiles

Checklists should be used to assess risk of bias or quality of studies when developing guidelines. NICE has some preferred checklists because of external collaborations and the endorsement of GRADE. These are indicated in this appendix. However, where the preferred checklist is not appropriate to address a particular review question, another appropriate checklist should be used according to the specific review question.

The reasons for using non-preferred checklists should be provided in the review protocol (see the section on planning the evidence review in the chapter on developing review questions and planning the evidence review).

The checklist should allow assessment of those features considered important – these may be study design-specific or specific to the topic. As such, inclusion of additional items, or making minor modifications, may be needed. Where this is the case, this should be documented, and agreed with the quality assurance team.

Quantitative review questions

Appraisal checklists: Systematic reviews

- **(Preferred)** [ROBIS: tool to assess risk of bias in systematic reviews](#)
- [Amstar](#)
- [Critical Appraisal Skills Programme (CASP) systematic review checklist](#)

For systematic reviews including individual participant data meta-analysis, reviewers can use the [PRISMA-IPD](#) to assess reporting standards, and [Wang 2021](#) includes a checklist that can be used for quality assessment.

Appraisal checklists: Intervention studies – randomised controlled trials (parallel)

- **(Preferred)** [Cochrane risk of bias (RoB) 2 tool](#)
- [Effective Practice and Organisation of Care (EPOC) RoB Tool (for randomised trial)](#)
- [CASP randomised control trials (RCT) checklist](#)

Appraisal checklists: Intervention studies – randomised controlled trials (cluster and crossover)

Cluster randomised trials

- **(Preferred)** [Cochrane RoB tool 2 for cluster randomised trials](#)

Crossover trials

- **(Preferred)** [Cochrane RoB tool 2 for crossover trials](#)

Appraisal checklists: Intervention studies – non-randomised studies

For more information on classifying non-randomised studies, see the [section on types of non-randomised study design in the NICE real-world evidence framework](#).

Non-randomised controlled trials (also called clinical controlled trials)

- **(Preferred)** [Cochrane ROBINS-I tool](#)
- [EPOC RoB Tool (for studies with a control group)](#)
- [GATE - Effective Public Health Practice Project quality assessment tool for quantitative studies](#)

Cohort study

- **(Preferred)** [Cochrane ROBINS-I tool](#)
- [EPOC RoB Tool (for studies with a control group)](#)
- [Cohort study checklist - CASP](#)
- [Newcastle-Ottowa quality assessment scale (for cohort study)](#)
- [Downs and Black checklist for measuring quality](#)
- [Effective Public Healthcare Panacea Project Quality Assessment Tool for Quantitative Studies](#)
- [Good ReseArch for Comparative Effectiveness (GRACE)](#)

Case control study

- **(Preferred)** [Case control study checklist - CASP](#)
- [EPOC RoB Tool (for studies with a control group)](#)
- [Newcastle-Ottowa quality assessment scale (for cohort study)](#)
- [Downs and Black checklist for measuring quality](#)

Controlled before-and-after study

- **(Preferred)** [EPOC RoB Tool (for before-and-after study)](#)

Interrupted time series

- **(Preferred)** [EPOC RoB Tool (for interrupted time series study)](#)

Cross sectional study

- **(Preferred)** [JBI checklist for analytical cross sectional studies](#)
- [AXIS](#)

Historical controlled cohort study

- **(Preferred)** [Cochrane ROBINS-I tool](#)
- [EPOC RoB Tool (for studies with a control group)](#)
- [Cohort study checklist - CASP](#)
- [Newcastle-Ottowa quality assessment scale (for cohort study)](#)

Case series (uncontrolled longitudinal study)

- **(Preferred)** [Institute of Health Economics (IHE) checklist for case series studies](#)

- [JBI checklist for case series](#)
- [National Heart Lung and Blood Institute tool for case series studies](#)

Note on the use of the ROBINS-I checklist

Although the ROBINS-I checklist is currently only validated and recommended for use with non-randomised controlled trials and cohort studies, there may be situations where a mix of non-randomised study types is included within a review. It can then be helpful to use this checklist across all included study types to maintain consistency of assessment. If this is done, additional care should be taken to ensure all relevant risks of bias for study designs for which ROBINS-I is not currently validated (such as case-control studies) are assessed.

Appraisal checklists: Diagnostic test accuracy studies

Note: This is for diagnostic test accuracy review where a typical 2×2 table is used to collect data on true positives, false positives, true negatives and false negative. No univariate or multivariate regression analysis is conducted.

- **(Preferred)** [University of Bristol QUADAS-2](#)
- [CASP diagnostic test accuracy checklist](#)

Appraisal checklists: Prediction studies for a prognosis or diagnosis

Note: This is for a prediction rule/model (PM) for a prognosis or a diagnosis (see [transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) statement for classifications](#)); these studies often use a cohort, cross sectional, or case control study design accompanied by multivariate regression modelling.

Examples for PM for a prognosis: QAdmission, PREDICT, risk-prediction model for falls.

Examples for PM for a diagnosis: QCancer, QRISK, Framingham Risk Score.

- **(Preferred)** [PROBAST](#) (see the [explanation of PROBAST](#))
- [CASP clinical prediction rule checklist](#)
- [Cochrane CHARMS checklist](#)

Appraisal checklists: Prognostic studies

Note: this is for simple association studies for particular risk factors or variables and their associations with a prognosis (with simple correlational analysis or regression analysis but where no prediction model has been developed). These studies often use a cohort, cross-sectional or case-control study design.

- **(Preferred)** QUIPS checklist

Appraisal checklists: Prevalence or incidence studies, or epidemiological studies

- **(Preferred)** JBI checklist for prevalence studies

Appraisal checklists: Other quantitative studies

Cross sectional survey or survey questionnaire study

- **(Preferred)** Centre for Evidence-Based Management (CEBM) checklist
- Boynton and Greenhalgh quality checklist for questionnaire surveys (see Box A.4)
- The BMJ checklist
- Roever checklist

Other studies on associations (other than for clinical diagnosis and prognosis)

Note: examples include the relationship between gender, age and exercise; the relationship between city or non-city dwelling and aggressive driving behaviour; the relationship between social economic status and sedentary lifestyle. These studies usually use cohort, cross-sectional or case-control study designs.

- **(Preferred)** Newcastle-Ottowa scale for assessing the quality of non-randomised studies in meta-analyses
- Cochrane EPOC risk of bias tool (for studies with a controlled group)
- Downs and Black checklist for measuring quality
- Effective Public Healthcare Panacea Project Quality Assessment Tool for Quantitative Studies

Qualitative review questions

Note: GRADE-CERQual should be used for qualitative evidence synthesis and presentation after quality assessment of individual studies has been done.

Appraisal checklists: Qualitative evidence syntheses

- **(Preferred)** Swedish Agency for Health Technology Assessment and Assessment of Social Services checklist
- MACACQuES tool
- Aromataris et al. 2015

Appraisal checklists: Primary qualitative studies

- **(Preferred)** Qualitative studies checklist - CASP
- Cochrane qualitative checklist
- JBI checklist for qualitative research
- Cabinet Office quality framework for social research
  - Consider the Cabinet Office checklist if the study is specific for qualitative evaluation concerned with the development and implementation of social policy, programmes and practice.

Mixed methods review question

Appraisal checklists: Mixed methods studies

Note: for when mixed methods studies are included in their entirety within a mixed methods review.

- **(Preferred)** Mixed Methods Appraisal Tool

Review questions that involve economic evaluations

Appraisal checklist: Economic evaluations

The checklist below can be used to determine whether an economic evaluation will provide evidence that is useful to inform the decision-making of the committee (see the chapter on incorporating economic evaluation). It judges the applicability and limitations of the study.

The robustness of the study results to methodological limitations may be apparent from reported sensitivity analyses. If not, judgement will be needed to assess

whether a limitation is likely to change the interpretation of results. The judgements should be recorded and presented in the evidence review document. The comments column in the checklist should be used to record reasons for these judgements, as well as additional details about the study where necessary.

Checklist: economic evaluations

Study identification		
Include author, title, reference, year of publication		
Guidance topic:		**Question no:**
Checklist completed by:		
Section 1: Applicability (relevance to specific review questions and the NICE reference case as described in section 7.5) This checklist should be used first to filter out irrelevant studies.	**Yes/partly/no/unclear/NA**	**Comments**
1.1 Is the study population appropriate for the review question?		
1.2 Are the interventions appropriate for the review question?		
1.3 Is the system in which the study was conducted sufficiently like the current UK context?		
1.4 Is the perspective for costs appropriate for the review question?		
1.5 Is the perspective for outcomes appropriate for the review question?		
1.6 Are all future costs and outcomes discounted appropriately?		
1.7 Are quality-adjusted life years (QALYs), derived using NICE's preferred methods, or an appropriate social care-related equivalent used as an outcome? If not, describe rationale and outcomes used in line with analytical perspectives taken (item 1.5 above).		
1.8 **Overall judgement:** Directly applicable/partially applicable/not applicable There is no need to use section 2 of the checklist if the study is considered 'not applicable'.		
Other comments:		

Section 2: Study limitations (the level of methodological quality) This checklist should be used once it has been decided that the study is sufficiently applicable to the context of the guideline	Yes/partly/no/unclear/NA	Comments
2.1 Does the model structure adequately reflect the nature of the topic under evaluation?		
2.2 Is the time horizon sufficiently long to reflect all important differences in costs and outcomes?		
2.3 Are all important and relevant outcomes included?		
2.4 Are the estimates of baseline outcomes from the best available source?		
2.5 Are the estimates of relative intervention effects from the best available source?		
2.6 Are all important and relevant costs included?		
2.7 Are the estimates of resource use from the best available source?		
2.8 Are the unit costs of resources from the best available source?		
2.9 Is an appropriate incremental analysis presented or can it be calculated from the data?		
2.10 Are all important parameters whose values are uncertain subjected to appropriate sensitivity analysis?		
2.11 Has no potential financial conflict of interest been declared?		
2.12 **Overall assessment:** Minor limitations/potentially serious limitations/very serious limitations		
Other comments:		

If the checklist below is not considered appropriate, other economic evaluation checklists such as Consolidated Health Economic Evaluation Reporting (CHEERS), can be used. The health technology assessment checklist for decision-analytic models (Philips et al. 2004) may give a more detailed assessment of the methodological quality of modelling studies.

For all questions:

- answer 'yes' if the study fully meets the criterion
- answer 'partly' if the study largely meets the criterion but differs in some important respect
- answer 'no' if the study deviates substantively from the criterion
- answer 'unclear' if the report provides insufficient information to judge whether the study complies with the criterion
- answer 'NA (not applicable)' if the criterion is not relevant in a particular instance.

For 'partly' or 'no' responses, use the comments column to explain how the study deviates from the criterion.

Section 1: Applicability

1.1 Is the study population appropriate for the review question?

The study population should be defined as precisely as possible and should be in line with that specified in the guideline scope and any related review protocols.

This includes consideration of appropriate subgroups that require special attention. For many interventions, the capacity to benefit will differ for study participants with different characteristics. This should be explored separately for each relevant subgroup as part of the base-case analysis by the provision of estimates of effectiveness and cost effectiveness.

The characteristics of participants or communities in each subgroup should be clearly defined and, ideally, should be identified based on an a priori expectation of differing effectiveness or cost effectiveness because of biologically, sociologically or economically plausible mechanisms, social characteristics or other clearly justified factors.

Answer 'yes' if the study population is fully in line with the review question and if the study differentiates appropriately between important subgroups. Answer 'partly' if the study population is like the population in the review question but: (i) it differs in some important respects; or (ii) the study fails to differentiate between important subgroups. Answer 'no' if the study population is substantively different from the population in the review question.

1.2 Are the interventions, services, or programmes appropriate for the review question?

All relevant alternatives should be included, as specified in the guideline scope and any related review protocols. These should include routine and best practice in UK settings, existing NICE guidance and other feasible options.

Answer 'yes' if the analysis includes all options considered relevant for the review question, even if it also includes other options that are not relevant. Answer 'partly' if the analysis omits 1 or more relevant options but still contains comparisons likely to be useful for the guideline. Answer 'no' if the analysis does not contain any relevant comparisons.

1.3 Is the system in which the study was conducted sufficiently like the current UK context?

This relates to the overall structure of the system within which the interventions were delivered. For example, an intervention might be delivered on a residential basis in 1 country whereas in the UK it is provided in the community. This may significantly influence the use of resources and costs, thus limiting the applicability of the results to a UK setting. In addition, old UK studies may be severely limited in terms of their relevance to current practice.

Answer 'yes' if the study was conducted within the UK and is sufficiently recent to reflect current practice. For non-UK or older UK studies, answer 'partly' if differences in the setting are unlikely to substantively change the cost-effectiveness estimates. Answer 'no' if the setting is so different that the results are unlikely to be applicable in the current UK context.

1.4 Is the perspective for costs appropriate for the review question?

The appropriate perspective will depend on the reference case that is relevant for a particular guideline or review question (see the [chapter on incorporating economic evaluation](#)); essentially the decision-making perspective determines the range of costs that should be included in the analysis. There may also be some question where consideration of multiple perspectives may be appropriate, such as for public health interventions delivered across different sectors.

For example, the perspective in the reference case for 'interventions with health outcomes funded by the NHS' is an NHS and PSS perspective. Productivity costs and costs borne by patients and carers that are not reimbursed by the NHS or PSS are usually excluded from this reference case (or any other NICE reference case).

Answer 'yes' if the perspective used is appropriate for the review question; also answer 'yes' if the study has taken a wider perspective, but the results are presented in such a way that the cost effectiveness can be calculated from the appropriate perspective. Answer 'partly' if the study has taken a wider or narrower perspective than that in the appropriate reference case, but the additional/omitted costs are small in relation to the total expected costs and are unlikely to change the cost-effectiveness result. Answer 'no' if the perspective is not appropriate, or the perspective taken is wider or narrower than that specified in the appropriate reference case and these costs are considered significant and likely to change cost-effectiveness.

1.5 Is the perspective for outcomes appropriate for the review question?

The appropriate perspective for outcomes will depend on the reference case that is relevant for a particular guideline or review question consistent with an objective of maximising benefits from available public sector resources:

- Interventions funded by the NHS with health outcomes:
  - All direct health effects, whether for individuals directly affected or, when relevant, other people (often family members or carers).
  - Non-health effects: not applicable.
- Interventions funded by the public sector with health and non-health outcomes:
  - All health effects on individuals.
  - Non-health effects: where deemed appropriate (decided on case-by-case basis, for example for local government and other non-health settings).
- Interventions funded by the public sector with a social care focus:
  - Effects on people for whom services are delivered (people using services or carers).
  - Non-health effects: capability or social care quality of life measures where an intervention results in both health and either capability or social care outcomes.

There may be some review questions where consideration of multiple perspectives for outcomes may be appropriate, where the outcomes of an intervention accrues across different sectors.

Answer 'yes' if the analysis includes all related effects and excludes non-related effects (or if such effects can be excluded from the results). Answer 'partly' if the analysis excludes some related effects or includes some non-related effects but these are small and unlikely to change the cost-effectiveness results. Answer 'no' if the analysis excludes significant effects or includes significant non-related effects that are likely to change the cost-effectiveness results.

1.6 Are all future costs and outcomes discounted appropriately?

The need to discount to a present value is widely accepted in economic evaluation, although the specific rate is variable across jurisdictions and over time. NICE considers that it is usually appropriate to discount costs and effects at the same rate. The annual rate of 3.5%, based on the recommendations of the UK Treasury for the discounting of costs, should be applied to both costs and effects. Sensitivity analyses using rates of 1.5% for both costs and effects may be presented alongside the reference-case analysis, particularly for public health interventions.

Answer 'yes' if both costs and effects are discounted at 3.5% per year (or at another rate considered appropriate). Answer 'partly' if costs and effects are discounted at a similar rate to that considered appropriate (for example, costs and effects are both discounted at 3% per year where the appropriate rate is 3.5% or the intervention assessed is public health and a discount rate of 1.5% has been applied to both costs and effects). Answer 'no' if costs or effects are not discounted, or if they are discounted at a rate (or rates) different from the rate considered appropriate (for example, 5% for both costs and effects, or 6% for costs and 1.5% for effects where the appropriate rate is 3.5%). Note in the comments column what discount rates have been used. If all costs and effects accrue within a short time (roughly a year), answer 'NA'.

1.7 Are QALYs derived using NICE's preferred methods, or an appropriate social care-related equivalent used as an outcome? If not, describe rationale

and outcomes used in line with analytical perspectives taken (see item 1.5 above).

The quality-adjusted life year (QALY) is a measure of a person's length of life weighted by a valuation of their health-related quality of life (HRQoL) over that period. For review questions where the QALY is not be the most appropriate measure of effects, other measures based on social care-related quality of life or capability may be used.

Answer:

- 'yes' if the effectiveness of the intervention is measured using QALYs and they are derived using EQ-5D administered to people with the condition or receiving the intervention or comparator with the UK population utility value set applied, or an appropriate social care-related equivalent
- 'partly' if the effectiveness of the intervention is measured using QALYs but derived using methods not in line with NICE's preferred methods
- 'no' if QALYs or a social care-related equivalent are not used. Use the comments column to describe the measure of effects used.

There may be circumstances when QALYs or a social care-related equivalent measure cannot be obtained or where the underlying assumptions are considered inappropriate. In such situations answer 'no', but consider retaining the study for appraisal. Similarly, answer 'no' but retain the study for appraisal if it does not include appropriate measures of effects but is still thought to be useful for committee decision-making: for example, if the evidence indicates that an intervention might be dominant, and estimates of the relative costs of the interventions from a cost-minimisation study are likely to be useful. When economic evaluations not using appropriate measures of effects are retained for full critical appraisal, use the comments column to note why.

1.8 Overall judgement

Classify the applicability of the economic evaluation to the guideline, the current UK situation and the context for the guideline as 1 of the following:

- **Directly applicable** – the study meets all applicability criteria, or fails to meet 1 or more applicability criteria but this is unlikely to change the conclusions about cost effectiveness.
- **Partially applicable** – the study fails to meet 1 or more of the applicability criteria, and this could change the conclusions about cost effectiveness.
- **Not applicable** – the study fails to meet 1 or more of the applicability criteria, and this is likely to change the conclusions about cost effectiveness. Such studies would usually be excluded from further consideration and there is no need to continue with the rest of the checklist.

Section 2: Study limitations

2.1 Does the model structure adequately reflect the nature of the topic under evaluation?

This relates to the choice of model and its structural elements (including cycle length in discrete time models, if appropriate). Model type and its structural aspects should be consistent with a coherent theory of the needs under evaluation. The selection of care pathways, whether individual states or branches in a decision tree, should be based on the underlying biological, sociological or economic processes of the topic under study and the potential impact (benefits and adverse consequences) of the interventions of interest.

Answer 'yes' if the model design and assumptions appropriately reflect the condition and interventions of interest. Answer 'partly' if there are aspects of the model design or assumptions that do not fully reflect the condition or interventions, but these are unlikely to change the cost-effectiveness results. Answer 'no' if the model omits some important aspect of the condition or intervention and this is likely to change the cost-effectiveness results. Answer 'NA' for economic evaluations based on data from a study which do not extrapolate intervention outcomes or costs beyond the study context or follow-up period.

2.2 Is the time horizon sufficiently long to reflect all important differences in costs and outcomes?

The time horizon is the period of analysis of the study: the length of follow-up for participants in a trial-based evaluation, or the period of time over which the costs and

outcomes for a cohort are tracked in a modelling study. This time horizon should always be the same for costs and outcomes, and should be long enough to include all relevant costs and outcomes relating to the intervention. A time horizon shorter than lifetime could be justified if there is no differential mortality effect between options, and the differences in costs, health/social care-related quality of life or other relevant outcomes relate to a relatively short period.

Answer 'yes' if the time horizon is sufficient to include all relevant costs and outcomes. Answer 'partly' if the time horizon may omit some relevant costs and outcomes but these are unlikely to change the cost-effectiveness results. Answer 'no' if the time horizon omits important costs and outcomes and this is likely to change the cost-effectiveness results.

2.3 Are all important and relevant outcomes included?

All relevant outcomes should include direct effects relating to harms from the intervention as well as any potential benefits.

Answer 'yes' if the analysis includes all relevant and important harms and benefits. Answer 'partly' if the analysis omits some harms or benefits but these would be unlikely to change the cost-effectiveness results. Answer 'no' if the analysis omits important harms and/or benefits that would be likely to change the cost-effectiveness results.

2.4 Are the estimates of baseline outcomes from the best available source?

The sources and methods for eliciting baseline probabilities should be described clearly. These data can be based on 'natural history' (outcomes in the absence of intervention), sourced from cohort studies. Baseline probabilities may also be derived from the control arms of experimental studies. Sometimes it may be necessary to rely on expert opinion for particular parameters.

Answer 'yes' if the estimates of baseline outcomes reflect the best available evidence, for example as identified from a recent well-conducted systematic review of the literature. Answer 'partly' if the estimates are not derived from the best available estimate but are likely to reflect outcomes for the relevant group of people in England (for example, if they are derived from a large UK-relevant cohort study).

Answer 'no' if the estimates are unlikely to reflect outcomes for the relevant group of people in England.

2.5 Are the estimates of relative intervention effects from the best available source?

Evidence on outcomes should be obtained from a systematic review with meta-analysis where appropriate. The best available estimate from the standpoint of guideline development will usually be one in line with the effectiveness evidence review undertaken for the guideline.

The methods and assumptions that are used to extrapolate short-term results to final outcomes should be clearly presented.

Answer 'yes' if the estimates of the effect of intervention appropriately reflect all relevant studies of the best available quality, as identified through a recent well-conducted systematic review of the literature, that is in line with the effectiveness evidence review undertaken for the guideline. Answer 'partly' if the estimates of the effect of intervention are not derived from a systematic review but are similar in magnitude to the best available estimates (for example, if the economic evaluation is based on a single large study with effects similar to pooled estimates from all relevant studies). Answer 'no' if the estimates of the effect of intervention are likely to differ substantively from the best available estimates.

2.6 Are all important and relevant costs included?

Costs related to the topic of interest and incurred in additional years of life gained because of the intervention should be included in the base-case analysis. Costs that are unrelated to the topic or intervention of interest should be excluded. If introduction of the intervention requires additional infrastructure to be put in place, consideration should be given to including such costs in the analysis.

Answer 'yes' if all important and relevant resource use and costs are included given the perspective and the research question in the economic study under consideration. Answer 'partly' if some relevant resource items are omitted but these are unlikely to affect the cost-effectiveness results. Answer 'no' if important resource items are omitted and these are likely to affect the cost-effectiveness results.

2.7 Are the estimates of resource use from the best available source?

It is important to quantify the effect of the interventions on resource use in terms of physical units (for example, days in care or contacts with practitioners) and valuing those effects in monetary terms using appropriate prices and unit costs. Evidence on resource use should be identified systematically. When expert opinion is used as a source of information, any formal methods used to elicit these data should be clearly reported.

Answer 'yes' if the estimates of resource use appropriately reflect all relevant evidence sources of the best available quality, as identified through a recent well-conducted systematic review of the literature. Answer 'partly' if the estimates of resource use are not derived from a systematic review but are similar in magnitude to the best available estimates. Answer 'no' if the estimates of resource use are likely to differ substantively from the best available estimates.

2.8 Are the unit costs of resources from the best available source?

Resources should be valued using the prices relevant to the agencies that deliver the interventions. A first point of reference in identifying costs and prices should be any current official listing published by relevant government departments.

When the acquisition price paid for a resource differs from the public list price, the public list price should be used in the base-case analysis. Sensitivity analysis should assess the implications of variations from this price. When cost data are taken from the literature, the methods used to identify the sources should be defined. When several alternative sources are available, a justification for the costs chosen should be provided and discrepancies between the sources explained. When appropriate, sensitivity analysis should have been undertaken to assess the implications for results of using alternative data sources.

Answer 'yes' if resources are valued using up-to-date prices relevant to the appropriate sectors. Answer 'partly' if the valuations of some resource items differ from current relevant unit costs but this is unlikely to change the cost-effectiveness results. Answer 'no' if the valuations of some resource items differ substantively from current relevant unit costs and this is likely to change the cost-effectiveness results.

2.9 Is an appropriate incremental analysis presented or can it be calculated from the data?

An appropriate incremental analysis is one that compares the expected costs and outcomes of one intervention with the expected costs and outcomes of the next-best non-dominated alternative.

Standard decision rules should be followed when combining costs and effects, and should reflect any situation where there is dominance or extended dominance. When there is a trade-off between costs and effects, the results should be presented as an incremental cost-effectiveness ratio (ICER): the ratio of the difference in mean costs to the difference in mean outcomes of a technology or intervention compared with the next best alternative. Where benefits are expressed as quality-adjusted life years (QALYs), in addition to ICERs, expected net monetary or health benefits can be presented using values placed on a QALY gained of £20,000 and £30,000. However, it may not be possible to place such values on other measures of benefits that are used in public health and social care economic evaluation.

For cost-consequences analyses (CCA), appropriate incremental analysis can only be done by selecting one of the consequences as the primary measure of effectiveness, providing the consequences are independent of one another.

Answer 'yes' if appropriate incremental results are presented, or if data are presented that allow the reader to calculate the incremental results. Answer 'no' if: (i) simple ratios of costs to effects are presented for each alternative compared with a standard intervention; or (ii) if options subject to simple or extended dominance are not excluded from the incremental analyses.

2.10 Are all important parameters whose values are uncertain subjected to appropriate sensitivity analysis?

There are several potential selection biases and uncertainties in any evaluation (trial- or model-based) and these should be identified and quantified where possible. There are 3 types of bias or uncertainty to consider:

- Structural uncertainty – for example in relation to the categorisation of different states of capability/wellbeing/health and the representation of different pathways

of care. These structural assumptions should be clearly documented and the evidence and rationale to support them provided. The impact of structural uncertainty on estimates of cost effectiveness should be explored by separate analyses of a representative range of plausible scenarios.

- Source of values to inform parameter estimates – the implications of different estimates of key parameters (such as estimates of relative effectiveness) must be reflected in sensitivity analyses (for example, through the inclusion of alternative scenarios). Inputs must be fully justified, and uncertainty explored by sensitivity analysis using alternative input values.

- Parameter precision – uncertainty around the mean capability/wellbeing/health and cost inputs in the model. Distributions should be assigned to characterise the uncertainty associated with the (precision of) mean parameter values. Probabilistic sensitivity analysis is preferred, as this enables the uncertainty associated with parameters to be simultaneously reflected in the results of the model. In non-linear decision models – when there is not a straight-line relationship between inputs and outputs of a model (such as Markov models) – probabilistic methods provide the best estimates of mean costs and outcomes. Simple decision trees are usually linear. The mean value, distribution around the mean, and the source and rationale for the supporting evidence should be clearly described for each parameter included in the model. Evidence about the extent of correlation between individual parameters should be considered carefully and reflected in the probabilistic analysis. Assumptions made about the correlations should be clearly presented.

Answer 'yes' if an extensive sensitivity analysis was undertaken that explored all key uncertainties in the economic evaluation. Answer 'partly' if the sensitivity analysis failed to explore some important uncertainties in the economic evaluation. Answer 'no' if the sensitivity analysis was very limited and omitted consideration of several important uncertainties, or if the range of values or distributions around parameters considered in the sensitivity analysis were not reported.

2.11 Has no potential financial conflict of interest been declared?

The British Medical Journal (BMJ) defines competing interests for its authors as follows: 'A competing interest exists when professional judgment concerning a

primary interest (such as patients' welfare or the validity of research) may be influenced by a secondary interest (such as financial gain or personal rivalry). It may arise for the authors of a BMJ article when they have a financial interest that may influence, probably without their knowing, their interpretation of their results or those of others.'

Whenever a potential financial conflict of interest is possible, this should be declared.

Answer 'yes' if the authors declare that they have no financial conflicts of interest. Answer 'no' if clear financial conflicts of interest are declared or apparent (for example, from the stated affiliation of the authors). Answer 'unclear' if the article does not indicate whether or not there are financial conflicts of interest.

2.12 Overall assessment

The overall methodological study quality of the economic evaluation should be classified as 1 of the following:

- **Minor limitations** – the study meets all quality criteria, or fails to meet 1 or more quality criteria but this is unlikely to change the conclusions about cost effectiveness.
- **Potentially serious limitations** – the study fails to meet 1 or more quality criteria, and this could change the conclusions about cost effectiveness.
- **Very serious limitations** – the study fails to meet 1 or more quality criteria, and this is highly likely to change the conclusions about cost effectiveness.

Cost-benefit analysis

If the economic evaluation is a cost-benefit analysis (CBA), the following questions should also be addressed:

1. Have money-costs and benefits, which are savings of future money-costs, been evaluated?

2. Have all important and relevant costs and outcomes for each alternative been quantified in money terms? If not, state which items were not quantified, and the likely extent of their importance in terms of influencing the benefit or cost ratio.

3. Has at least 1 of net present value, benefit or cost ratio and payback period been estimated?

4. Were any assumptions of materiality made? That is, were there any items where costs or benefits (or both) were sufficiently small that their addition to the analysis would not have changed any recommendations in the guidelines?

Cost-consequence analysis

Cost-consequence analysis (CCA) is most useful for evaluating public health and social care interventions that report a diverse range of outcomes in discrete categories that cannot be aggregated into a single metric. It may also be used to either supplement a cost-utility analysis (CUA), where important relevant outcomes would be excluded, or as a necessary first step to conducting a CBA.

If the economic evaluation is a CCA, the following questions should also be addressed:

1. Have all important and relevant costs and outcomes for each alternative been quantified, where appropriate? If not, state which items were not quantified. Were they still used in the CCA and how were they used?

2. Were any assumptions of materiality made to restrict the number of consequences considered? That is, were there any items where costs or benefits (or both) were sufficiently small that their addition to the analysis would not have changed any recommendations in the guidelines?

3. Was any analysis of correlation between consequences carried out to help control for double counting?

4. Was there any indication of the relative importance of the different consequences by a suggested weighting of them?

5. Were there any theoretical relationships between consequences that could have been taken into account in determining weights?

6. Were the consequences considered one by one to see if a decision could be made based on a single consequence or a combination of a small number of consequences?

7. Were the consequences considered in subgroups of all the consequences in the analysis to see if a decision could be made based on a particular subgroup?

Supporting references

Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—Explanation and elaboration: A report of the ISPOR health economic evaluations publication guidelines good reporting practices task force. Value Health 2013;16:231-50.

National Institute for Health and Clinical Excellence (2008) Social value judgements: principles for the development of NICE guidance (second edition). London: National Institute for Health and Clinical Excellence

Philips Z, Ginnelly L, Sculpher M et al. (2004) Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technology Assessment 8 (36)

Evers, S, Goossens M, de Vet H et al. (2005) Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. International Journal of Technology Assessment in Health Care 21: 240–5

Review questions where cannot use a mix of checklists

Appraisal checklists: generic

There may be some reviews where it is not helpful to use different checklists for the different study designs (for example, in a complex mixed methods review). In such cases, a single checklist that can be applied to different study designs may be used.

Shepherd J, Kavanagh J, Picot J et al. (2010) The effectiveness and cost-effectiveness of behavioural interventions for the prevention of sexually transmitted infections in young people aged 13–19: a systematic review and economic evaluation. Health Technol Assess 14(7) Appendix 5

Taylor BJ, Dempster M, Donnelly M (2007) Grading gems: appraising the quality of research for social work and social care. British Journal of Social Work 37: 335

Examples of evidence tables

This section includes examples of evidence tables for those study designs that are expected to be used in the evidence reviews for NICE guidelines.

Below are examples of the type of information and data NICE requires in table format in evidence reviews. It is not possible to provide a fixed template for all evidence tables that will suit all topics or that can be produced by different evidence management software. The range, type, quantity and quality of evidence identified will inevitably vary and these tables are presented as examples only of how information and data should be presented.

If additional analysis or additional calculation (for example, calculating numbers needed to treat, odds ratios, risk ratios) of data is required and feasible, these must be clearly noted as 'calculated by the review team'.

Example of an evidence table for systematic reviews

Potentially relevant information to include (specific items to include should be decided for each review)

- Bibliographic reference: authors, year (note: year, article title, journal, volume, pages to go in detailed reference list).

- Review type: for example, systematic review with meta-analysis.

- Number of studies: total number of studies included in the review.

- Study characteristics: characteristics relevant to the area of interest: study design, other restrictions.

- Intervention: treatment, service, procedure or test studied. If important for the study, specify duration of treatment.

- Setting: the settings where the interventions was delivered (for example, care homes).

- Comparison: alternative treatment or 'standard care'.

- Outcome measures: list all outcome measures defined in the guideline review protocol, including associated harms.

- Results: for example, summary effect size from a meta-analysis.

- Source of funding: for example, the Department of Health and Social Care or Economic and Social Research Council. Also detail the role of funding organisations.

- Quality assessment: Document any concerns about quality which can be used to provide an overall assessment of the review (for example, rating from quality checklist).

- Additional comments: additional characteristics and/or interpretations of the review that the reviewer wishes to record. These might include important flaws and limitations in the review not identifiable from other data in the table, and additional questions or issues that will need to be considered but do not figure in the results tables in the review.

Title: (review question)

Bibliographic reference	Review design	Study quality	Review search parameters	Review population and setting	Intervention(s)	Outcomes and methods of analysis	Results	Limitations	Additional comments
			Sources Methods of searching Dates Inc/exc criteria Number of studies	Details (demographics) Missing information	Intervention in detail (who, where, when) Controls/comparator also in detail		Objective/subjective Time points Health inequalities impact	Identified by authors Identified by developers	Source of funding

The detailed information under each heading should be agreed at the review protocol stage and be completed consistently throughout the review.

Example of an evidence table for intervention studies

Potentially relevant information to include (specific items to include should be decided for each review)

- Bibliographic reference: authors, year, article title, journal, volume, pages.

- Study type: for example, randomised controlled trial, cohort or case-control studies.

- Number of participants: total number of participants included in the study, including number of participants in each arm, with inclusion and exclusion criteria. Also record the numbers of participants who started and completed the study.

- Participant characteristics: characteristics relevant to the area of interest: age, sex, ethnic origin, condition status and comorbidity.

- Intervention: treatment, service, procedure, or test studied. If important for the study, specify duration of treatment.

- Setting: the settings where the interventions was delivered (for example, care homes).

- Comparison: alternative treatment or 'standard care'.

- Length of follow-up: the length of time that participants take part in the study for, from first staging treatment until either a pre-specified endpoint or the end of the data-gathering phase is reached. If the study is stopped earlier than originally planned for any reason, this should be noted here.

- Outcome measures: list all outcome measures defined in the review protocol, including associated harms.

- Effect size: for example, raw data from the study that allow further analyses, as required. Give confidence intervals for relevant outcome types whenever possible.

- Source of funding: for example, the Department of Health and Social Care or Economic and Social Research Council. Also detail the role of funding organisations.

- Quality assessment: Document any concerns about quality which can be used to provide an overall assessment of each study (for example, rating from quality checklist) for use in GRADE assessment

- Additional comments: additional characteristics and/or interpretations of the studies that the reviewer wishes to record. These might include important flaws and limitations in the study not identifiable from other data in the table, and additional questions or issues that will need to be considered but do not figure in the results tables in the study

Title: (review question)

Bibliographic reference	Study type	Study quality	Intervention	Comparator	Method of allocation	Setting	Number of participants	Participant characteristics	Length of follow- up	Methods of analysis	Outcomes/ Results	Limitations	Additional comments
			Intervention in detail (who, where, when)		Methods use to minimize confounders	Country Location	Power information Method of recruitment	Information on representativeness	Loss to follow- up	ITT or completer Adjustments for baseline differences	Objective/ subjective Time points Health inequalities impact	Identified by authors Identified by developers	Evidence gaps Further research identified

The detailed information under each heading should be agreed at the review protocol stage and be completed consistently throughout the review.

Example of an evidence table for studies of diagnostic test accuracy

Potentially relevant information to include (specific items to include should be decided for each review)

- Bibliographic reference: authors, year, article title, journal, volume, pages.

- Study type: for example, cross-sectional, cohort or case–control studies.

- Number of participants: total number of patients included in the study, with inclusion and exclusion criteria.

- Prevalence: proportion of people with the disease in the population at risk.

- Participant characteristics: characteristics relevant to the area of interest: age, sex, ethnic origin, comorbidity, disease status, community- or hospital-based.

- Type of test (index test): description of the diagnostic test used in the study. Specify the test threshold where applicable.

- Reference standard: used as a marker of the "correct" classification against which the index tests are compared. Specify if it is a 'gold standard' or 'current best practice'.

- Sensitivity: proportion of individuals classified as positive by the gold (or reference) standard who are correctly identified by the study test.

- Specificity: proportion of individuals classified as negative by the gold (or reference) standard who are correctly identified by the study test.

- Raw data for 2×2 table: study data collected from tests to calculate sensitivity, specificity, positive and negative likelihood ratios, and positive and negative predictive values.

- Positive likelihood ratio: the likelihood of having the disease, as opposed to not having the disease, having tested positive for it (an estimate of the amount by which a positive test result increases the probability of having the disease that was tested for). Negative likelihood ratio: the likelihood of having the disease, as opposed to not having the disease, having tested negative for it (an estimate of the amount by which a negative test result decreases the probability of having the disease that was tested for).

- Positive predictive value: proportion of individuals with a positive test result who have the disease.

- Negative predictive value: proportion of individuals with a negative test result who do not have the disease.

- Source of funding: government funding (for example, NHS), voluntary or charity (for example, Wellcome Trust), pharmaceutical company; and the role of funding organisations.

- Quality assessment: Document any concerns about quality which can be used to provide an overall assessment of each study (for example QUADAS-2) for use in GRADE or modified GRADE assessment.
- Additional comments: additional characteristics and/or interpretations of the studies that the reviewer wishes to record. These might include important flaws in the study not identifiable from other data in the table, and additional questions or issues that will need to be considered but do not figure in the results tables in the study (for example, if a test is one of a sequence of tests; if its utility was determined).

Title: (review question)

Bibliographic reference	Study type	Study quality	Type of test (index test)	Reference standard	Number of participants	Prevalence	Participant characteristics	Sensitivity and specificity or raw data for 2x2 table	Other metrics: Positive and negative likelihood ratios and/or Positive and negative predictive values	Additional comments

The detailed information under each heading should be agreed at the review protocol stage and be completed consistently throughout the review.

Example of an evidence table for prognostic studies or prediction rule or model for prognosis or diagnosis

Potentially relevant information to include (specific items to include should be decided for each review)

- Bibliographic reference: authors, year, article title, journal, volume, pages.

- Study type: for example, cohort, nested cohort, case series.

- Number of participants: total number of patients included in the study, including number and proportion of patients with prognostic factors or risk factors, or signs and symptoms, with inclusion and exclusion criteria. Also record numbers of patients who started and completed the study.

- Participant characteristics: characteristics relevant to the area of interest: age, sex, ethnic origin, comorbidity, disease status, community- or hospital-based. Include method used to select participants.

- Prognostic factors or risk factors or signs or symptoms: include details of method of measurement.

- Confounding factors adjusted for in the analyses undertaken.

- Length of follow-up: the length of time that patients take part in the study for, from entry until either a pre-specified endpoint (for example, death, specified length of disease-free remission) or the end of the data-gathering phase is reached. If the study is stopped earlier than originally planned for any reason, this should be noted here.

- Outcome measures: all outcome measures should be listed, with each on a separate line.

- Results: odds ratio or adjusted odds ratio or relative risk or hazard ratio associated with the prognostic factor of interest or risk factors or signs or symptoms, absolute risk of event in baseline group; time-to-event analysis. For clinical prediction rule/model for diagnosis results may be reported as accuracy metrics (for example, sensitivity, specificity, +LR, -LR, PPV, NPV).

- Source of funding: government funding (for example, NHS), voluntary or charity (for example, Wellcome Trust), pharmaceutical company; and the role of funding organisations.

- Quality assessment: Document any concerns about quality which can be used to provide an overall assessment of each study (for example, rating from quality checklist) for use in GRADE or modified GRADE assessment.

- Additional comments: additional characteristics and/or interpretations of the studies that the reviewer wishes to record. These might include important flaws in the study not identifiable from other data in the table, and additional questions or issues that will need to be considered but do not figure in the results tables in the study.

Title: (review question)

Bibliographic reference	Study type	Study quality	Prognostic factor(s) or risk factor(s) or sign(s)/symptom(s)	Confounding factors adjusted for	Number of participants	Participant characteristics	Length of follow-up	Outcome measures	Results	Additional comments

The detailed information under each heading should be agreed at the review protocol stage and be completed consistently throughout the review.

Example of an evidence table for qualitative studies

Potentially relevant information to include (specific items to include should be decided for each review)

- Bibliographic reference: authors, year, article title, journal, volume, pages.

- Research question: what were the research questions?

- Theoretical approach: what theoretical approach (for example, grounded theory, interpretive phenomenological analysis) does the study take (if specified)?

- Data collection: how were the data collected? Give details of:

  - methods

  - by whom

  - when.

- Method and process of analysis: what methods were used to analyse the data (for example, constant comparative method)?

- Population and sample collection: what population was the sample recruited from? Include the following information:

  - how they were recruited (for example, specify the type of purposive sampling)

  - how many participants were recruited

  - specific exclusion criteria

  - specific inclusion criteria.

- Settings: The settings where the qualitative study was undertaken.

- Key themes: list all relevant to this review (with illustrative quotes if available).

- Source of funding: for example, the Department of Health and Social Care or Economic and Social Research Council, and the role of funding organisations.

- Quality assessment: Document any concerns about quality which can be used to provide an overall assessment of each study (for example, rating from quality checklist) for use in CERQual assessment.

- Additional comments: both those identified by the authors and those identified by the reviewer.

- Evidence gaps or recommendations for future research.

Title: (review question)

Bibliographic reference	Study quality	Research question	Theoretical approach	Data collection	Method and process of analysis	Population and sample collection	Key themes	Limitations	Additional comments
							Quotes, where helpful or illustrative		

The detailed information under each heading should be agreed at the review protocol stage and be completed consistently throughout the review.

Example of an evidence table for economic evaluation studies

Potentially relevant information to include (specific items to include should be decided for each review)

- Bibliographic reference: authors, year, article title, journal, volume, pages.

- Study type: for example, randomised controlled trial with economic evaluation.

- Number of participants: total number of participants included in the study, including number of participants in each arm, with inclusion and exclusion criteria. Also record the numbers of participants who started and completed the study.

- Participant characteristics: characteristics relevant to the area of interest: age, sex, ethnic origin, condition status and comorbidity.

- Intervention: treatment, service, procedure, or test studied. If important for the study, specify duration of treatment.

- Setting: the settings where the interventions was delivered (for example, care homes).

- Comparison: alternative treatment or 'standard care'.

- Length of follow-up: the length of time that participants take part in the study for, from first staging treatment until either a pre-specified endpoint or the end of the data-gathering phase is reached. If the study is stopped earlier than originally planned for any reason, this should be noted here.

- Outcome measures: list all outcome measures defined in the review protocol, including associated harms.

- Effect size: for example, raw data from the study that allow further analyses, as required. Give confidence intervals for relevant outcome types whenever possible.

- Source of funding: for example, the Department of Health and Social Care or Economic and Social Research Council. Also detail the role of funding organisations.

- Quality assessment: Document any concerns about quality with respect to the limitations and applicability to provide an overall assessment of each study assessment.

- Additional comments: additional characteristics or interpretations of the studies that the reviewer wishes to record. These might include important flaws and limitations in the study not identifiable from other data in the table, and additional questions or issues that will need to be considered but do not figure in the results tables in the study.

Bibliographic reference	Study type	Study quality	Setting	Intervention	Comparator	Number of participants	Participant characteristics	Methods of analysis	Results	Limitations	Additional comments
		Applicability	Country Setting Location	Intervention in detail (who, where, when)	As for intervention		Source population	Type of economic analysis Data sources Time horizon Discount rates Perspective Measures of uncertainty	Objective/ subjective Time points Health inequalities impact Primary results Secondary analysis Modelling method	Identified by authors Identified by developers	Source of funding Evidence gaps Further research identified

The detailed information under each heading should be agreed at the review protocol stage and be completed consistently throughout the review.

Please complete for all headings and note where data is 'Not reported' or 'Not applicable'.

GRADE profile and economic evidence profile

This aims to give examples of profiles that can be used when developing guidelines. The decision about which information to include in the profile should be made as part of the review protocol development. The profile should include features considered important – these may be study design specific or specific to the topic. As such, additional items may need to be included, or minor modification made. Where this is the case, this should be documented and agreed with the quality assurance team.

Worked example of a GRADE profile: Review question: Should duloxetine versus placebo be used for painful diabetic neuropathy?

Outcome	No. of studies	Design	Certainty of the evidence: Risk of bias Inconsistency Indirectness Imprecision	Other considerations	No of patients: Duloxetine	No of patients: Placebo	Relative effect (95% CI)	Absolute effect	Quality	Importance
Patient-reported 30% pain reduction (follow-up 12 weeks)	2[1]	Randomised trials	No serious risk of bias Serious inconsistency[2] No serious indirectness No serious imprecision	None	220/327	111/215	RR 1.33 (0.95 to 1.88)	17 more per 100 (from 3 fewer to 45 more)	Moderate	Critical
No. of withdrawals due to adverse effects (follow-up 12 weeks)	4[3]	Randomised trials	No serious risk of bias No serious inconsistency No serious indirectness No serious imprecision	None	113/906	21/448	RR 2.63 (1.68 to 4.12)	8 more per 100 (from 3 more to 15 more)	High	Critical
Dizziness (adverse effects) (follow-up 12 weeks)	3[6]	Randomised trials	No serious risk of bias No serious inconsistency No serious indirectness Serious imprecision[5]	None	90/674	26/332	RR 1.81 (1.17 to 2.79)	6 more per 100 (from 1 more to 14 more)	Moderate	Critical
GI disturbances (adverse effects) (follow-up 12 weeks)	2[8]	Randomised trials	No serious risk of bias No serious inconsistency No serious indirectness	None	28/332	8/217	RR 2.53 (1.13 to 5.67)	6 more per 100 (from 0	Moderate	Important

Outcome	No. of studies	Design	Certainty of the evidence: Risk of bias Inconsistency Indirectness Imprecision	Other considerations	No of patients: Duloxetine	No of patients: Placebo	Relative effect (95% CI)	Absolute effect	Quality	Importance
			Serious imprecision[5]					more to 17 more)		
Any adverse effects (non-specified) (follow-up 12 weeks)	1[9]	Randomised trials	No serious risk of bias No serious inconsistency No serious indirectness Very serious imprecision[10]	None	86/106	78/109	RR 1.13 (0.98 to 1.32)	9 more per 100 (from 1 fewer to 23 more)	Low	Critical

[1] Gao et al. (2010); Wernicke et al. (2006).

[2] Substantial heterogeneity, random-effect model was used. Potential sources of heterogeneity: i) Gao et al. (2010) – ITT data available, used flexible dose between 30 mg and 120 mg, non-pharmaceutical company funded; ii) Wernicke et al. (2006) – only per-protocol data available, combined 2 fixed doses (60 mg and 120 mg), pharmaceutical company funded.

[3] Gao et al. (2010); Goldstein et al. (2005); Raskin et al. (2005); Wernicke et al. (2006).

[4] Substantial heterogeneity, random-effect model was used. Potential sources of heterogeneity: i) Gao et al. (2010) – used flexible dose between 30 mg and 120 mg, non-pharmaceutical company funded; ii) Goldstein et al. (2005), Raskin et al. (2005) and Wernicke et al. (2006) – combined different fixed doses (20 mg, 60 mg and 120 mg), pharmaceutical company funded.

[5] Confidence interval crossed 1 end of default MID.

[6] Gao et al. (2010); Goldstein et al. (2005); Wernicke et al. (2006).

[7] Gao et al. (2010); Goldstein et al. (2005).

[8] Gao et al. (2010); Wernicke et al. (2006).

[9] Gao et al. (2010).

[10] Confidence interval crossed both ends of default MID.

Abbreviations: CI, confidence interval; GI, gastrointestinal; ITT, intention to treat; MID, minimal important difference; RR, relative risk.

Example of an uncompleted GRADE profile

Outcome	No. of studies	Design	Certainty of the evidence: Risk of bias Inconsistency Indirectness Imprecision	Other considerations	No of patients: Duloxetine	No of patients: Placebo	Relative effect (95% CI)	Absolute effect	Quality	Importance

Example of an uncompleted CERQual evidence profile

Summary of review finding (theme)	Studies contributing to the review finding	Methodological limitations	Coherence	Adequacy	Relevance	CERQual assessment of confidence in the evidence
Finding 1						
Finding 2						
Finding 3						

[References, abbreviations and other footnotes].

Worked example of an economic evidence profile

Adapted from Crohn's disease: management in adults, children and young people (NICE guideline CG152).

Systematic review of economic evaluations of budesonide for maintenance of remission in Crohn's disease

Study	Limitations	Applicability	Other comments	Incremental costs	Incremental effects	Incremental cost effectiveness	Uncertainty

Noble 1998 Budesonide controlled ileal release versus no maintenance therapy	Potentially serious limitations[1,2]	Partially applicable[3]	Study employed a Markov decision-analytic model with a 1-year time horizon	£115	0.017 QALYs[5]	£6,981 per QALY gained	Incremental cost effectiveness ratio (ICER) decreases significantly if the cost of surgery is increased.
National Clinical Guideline Centre model Oral budesonide versus no maintenance therapy[4]	Potentially serious limitations[2]	Directly applicable	Study employed a Markov decision-analytic model with a 2-year time horizon	£477[6] £150[7]	0.012 QALYs[6] 0.012 QALYs[7]	£40,392 per QALY gained[6] £15,070 per QALY gained[7]	No treatment most cost-effective option when baseline risk of relapse decreased. In the probabilistic sensitivity analysis (PSA), probability of budesonide being the most cost-effective treatment at willingness-to-pay threshold of £20,000 per QALY gained ranged from 0 to 8%

[1] Modelling was undertaken over a short time horizon and no probabilistic sensitivity analysis was conducted.

[2] Specific costs and disutilities of drug-related adverse events could not be explicitly modelled. Adverse events were captured by modelling treatment- specific withdrawal rates. This may have overestimated the cost effectiveness of maintenance treatment.

[3] The cost-effectiveness model was designed to reflect the management of Crohn's disease in the Swedish healthcare setting. Although a cost per QALY estimate was reported, it was not based on health-related quality of life values elicited from patients.

[4] The NCGC model compared a number of different maintenance treatments.

[5] Figures may differ because of rounding off.

[6] Conservative 4-line model. Conservative treatment effects were used and people relapsing while on azathioprine maintenance treatment had a different induction sequence.

[7] Conservative three-line model. Conservative treatment effects were used and people were assumed to have the same 6 induction sequence regardless of maintenance treatment.

Example of an uncompleted economic evidence profile

Study	Limitations	Applicability	Other comments	Incremental Costs	Incremental Effects	Incremental Cost effectiveness	Uncertainty

[References, abbreviations and other footnotes].

Notes on use of economic evidence profiles

The economic evidence profile includes columns for the overall assessments of study limitations and applicability as identified using an appropriate checklist. There is also a comments column to note particular issues that the committee should consider when assessing the economic evidence. Footnotes (underneath the table as normal text) should be used to explain the reasons for quality assessments.

The results of the economic evaluations can be presented in the form of a best-available estimate or range for the incremental cost, the incremental effect and, where relevant, the ICER or net benefit estimate. A summary of the extent of uncertainty about the estimates should also be presented in the economic evidence profile. This should reflect the results of deterministic or probabilistic sensitivity analyses or stochastic analyses of trial data, as appropriate.

Each economic evaluation should usually be presented in a separate row of the economic evidence profile. If large numbers of economic evaluations of sufficiently high quality and applicability are available, a single row could be used to summarise several studies based on shared characteristics; this should be explicitly justified in a footnote.

Inconsistency between the results of economic evaluations will be shown by differences between rows of the economic evidence profile (a separate column examining 'consistency' is therefore unnecessary). The committee should consider the implications of any unexplained differences between model results when assessing the body of evidence and drawing up recommendations. This includes clearly explaining the committee's preference for certain results when forming recommendations.

If results are available for 2 or more subgroups, these should be presented in separate economic evidence profile tables or as separate rows within a single table.

Costs and cost-effectiveness estimates should only be presented for appropriate incremental comparisons; that is, where an intervention is compared with the next most expensive non-dominated option. If comparisons are relevant only for some groups of the population (for example, people who cannot tolerate 1 or more of the

other options, or for whom 1 or more of the options is contraindicated), this should be stated in a footnote to the economic evidence profile.